Application progress of radionuclide imaging and therapy in neuroendocrine tumors
10.3760/cma.j.issn.2095-2848.2019.09.015
- VernacularTitle: 放射性核素诊治神经内分泌肿瘤的应用进展
- Author:
Huipan LIU
1
;
Yue CHEN
Author Information
1. Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
- Publication Type:Review
- Keywords:
Neuroendocrine tumors;
DOTATATE;
Lutetium;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(9):564-567
- CountryChina
- Language:Chinese
-
Abstract:
Some subtypes of somatostatin receptors (SSTRs) are overexpressed in neuroendocrine tumors (NETs). 177Lu-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-D-Phel-Tyr3-Thr8-octreotide (DOTATATE) is a somatostatin analogue that can be combined with somatostatin receptor specifically, which plays an important role not only in early diagnosis, clinical staging, treatment guiding, recurrence detection and metastasis of NETs, but also in the targeted radionuclide therapy of tumors. The side effect of peptide receptor radionuclide therapy is relatively mild, which is of great clinical significance for prolonging patients′ survival, improving symptoms and the quality of life.
